ROBINS HARLAN S sold $8.5M of ADPT
ROBINS HARLAN S (Chief Scientific Officer) sold 386,240 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $22.01 ($21.74–$22.45, $8.50M total) across 2 trades on 2026-07-02 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the disclosed sale size, price range ($21.7400–$22.4500), and that it was executed under a pre-arranged 10b5-1 plan.
Market read
Traders may monitor for follow-on insider activity, but this specific disclosure alone is unlikely to drive a fundamental repricing.
What to watch
The filing does not state whether other insiders sold/bought around the same time, nor does it provide post-sale performance context.
Background
The article is an SEC Form 4 insider transaction disclosure for Adaptive Biotechnologies (ADPT).
Ticker impact
Form 4 shows Chief Scientific Officer Robins Harlan S sold 386,240 ADPT shares for about $8.5M under a 10b5-1 plan.
Likely limited/short-lived impact; any move would be sentiment-driven rather than catalyst-driven.
The filing is a routine 10b5-1 sale disclosure with no accompanying guidance, deal, or regulatory/clinical update in the text.
Market effects
Minimal; no sector-wide signal is provided beyond a single-company insider transaction.
None indicated.
None indicated.
Counterpoint
Because it’s a 10b5-1 plan, the sale may be largely mechanical and not a bearish read-through; traders may discount it.
Key entities
- issuerAdaptive Biotechnologies Corp
Subject of the Form 4 insider sale disclosure.
- insiderRobins Harlan S
Chief Scientific Officer who sold 386,240 shares.